A Study to Assess IPN01194 in Adults With Advanced Solid Tumours
Phase 1/2
220
about 4 years
18+
5 sites in CA, CT, TN +1
About this study
This trial is testing a treatment called IPN01194 in adults with advanced solid tumors. The goal is to determine the right dose, safety, and effectiveness of IPN01194.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take IPN01194
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Phase 1: Percentage of participants experiencing Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TE SAEs), Phase 1: Percentage of participants with dose limiting toxicity (DLT), Phase 2a: Objective response rate (ORR)
Secondary: Phase 1: Geometric mean ratio of Cmax of IPN01194 administered in fed state relative to fasted state, Phase 1: Maximum observed drug concentration (Cmax) after single and multiple doses of IPN01194, Phase 1: Objective response rate (ORR), Phase 1: Time to maximum observed drug concentration (Tmax) after single and multiple doses of IPN01194, Phase 2a: Disease control rate (DCR), Phase 2a: Duration of response (DoR), Phase 2a: PFS rate at 4 months, Phase 2a: Percentage of participants with TEAEs and TE SAEs
Oncology